top of page
Doctor's Appointment
MITOPE-LOGO FINAL.png

PURPOSE:
The primary objective is to evaluate the efficacy and safety of RSO-021 in participants with Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma.

Have this trial number available

NCT05278975

US NIH: clinicaltrials.gov

DATES: Starts: March 31, 2022 |  Ends: April 1, 2025

US NIH: clinicaltrials.gov  NCT05278975

Mesothelioma UK: mesothelioma.uk.com or call 

Freephone: 0800 169 2409

NIHR UK: bepartofresearch.nihr.ac.uk

www.ecmcnetwork.org.uk

MITOPE is sponsored by RS Oncology, LLC

Eligibility

MPE

Diagnosed with Malignant Pleural Effusion due to metastatic disease or mesothelioma

IPC 

Has IPC installed or is a good candidate for IPC installation

18.png

Performance
Status

Has ECOG PS < 1

Accepting Patient Referrals 

By choosing to participate in the Mitope clinical trial, patients will have access to novel therapies, that has the potential to be more effective than standard treatments and contribute to research for the future. Professional healthcare providers can refer patients by contacting us mitope@rsoncology.com

MITOPE Locations

Scientist on Tablet

Contact Us

The patient is eligible due to

Thank you.

bottom of page